BCHE and Alzheimer disease: Unlike the peripheral side effects associated with general ChE inhibitors, such as cramps, gastrointestinal issues, and the risk of bradycardia, selective BChE inhibition circumvents these peripheral parasympathomimetic effects.52,53 The safety factor of enzyme inhibition is demonstrated by the fact that both animal and human BChE nullizygotes are viable and lead normal lifespans.54,55 Despite the existence of numerous cholinesterase inhibitors documented in the literature, the ongoing quest for novel scaffolds targeting AD persists as an essential scientific grail.